Findings

What do systematic reviews say?

10 questions · 11 findings · 2 reviews · Gut · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 9.1%GRADE not reported 0 · 0%Very low 1 · 9.1%Low 9 · 81.8%Moderate 0 · 0%High 0 · 0%

Antidepressants vs placebo

Anxiety · people with inflammatory bowel disease

2 findings from 1 review

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low
Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Antidepressants vs placebo

Depression at 12 weeks · people with inflammatory bowel disease

1 finding from 1 review

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

Antidepressants vs placebo

Depression at 12 months · people with inflammatory bowel disease

1 finding from 1 review

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Antidepressants vs placebo

Adverse events at 12 months · people with inflammatory bowel disease

Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).

1 finding from 1 review

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
RR 2.29 [0.78, 6.73]
1 study · 26 participants
Low

Antidepressants vs placebo

Quality of life · people with inflammatory bowel disease

1 finding from 1 review

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 70 participants
Low

Antidepressants vs placebo

Pain · people with inflammatory bowel disease

The review found no eligible studies for this question.

1 finding from 1 review

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antidepressants vs placebo

Maintenance of remission · people with inflammatory bowel disease

Antidepressants showed no clear difference in maintenance of remission at 12 months compared with placebo (low certainty).

1 finding from 1 review

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
RR 0.96 [0.55, 1.69]
1 study · 26 participants
Low

Antidepressants vs placebo

Endoscopic relapse · people with inflammatory bowel disease

It is very uncertain whether antidepressants changes endoscopic relapse at 12 months compared with placebo (very low certainty).

1 finding from 1 review

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease 2019 · Cochrane Headline outcomes only
RR 0.14 [0.01, 2.65]
1 study · 60 participants
Very low

Antidepressants vs placebo

Treatment success (caries lesion arrest or restoration survival) · children (4 to 18 years) with functional abdominal pain disorders

Antidepressant showed no clear difference in treatment success compared with placebo (low certainty).

1 finding from 1 review

Antidepressants for functional abdominal pain disorders in children and adolescents 2021 · Cochrane Headline outcomes only
RR 1.17 [0.87, 1.56]
2 studies · 205 participants
Low

Antidepressants vs placebo

Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders

Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Antidepressants for functional abdominal pain disorders in children and adolescents 2021 · Cochrane Headline outcomes only
RR 3.17 [0.65, 15.33]
3 studies · 238 participants
Low